SNDX Syndax Pharmaceuticals Inc.

7.04
-0.6  -8%
Previous Close 7.64
Open 7.65
Price To Book 4.35
Market Cap 191,069,007
Shares 27,140,484
Volume 130,945
Short Ratio
Av. Daily Volume 113,314
Stock charts supplied by TradingView

NewsSee all news

  1. Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook

    WALTHAM, Mass., Jan. 10, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  2. Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease

    WALTHAM, Mass., Dec. 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  3. Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias

    WALTHAM, Mass., Dec. 9, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  4. Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update

    WALTHAM, Mass., Nov. 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  5. Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

    WALTHAM, Mass., Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 603
Ovarian cancer
Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 2 updated data to be presented September 24, 2018 did not meet prespecified ORR endpoint.
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC), colorectal cancer
Phase 3 PFS date did not meet primary endpoint - October 25, 2018. OS final analysis due 2Q 2020.
E2112
HR+, HER2- breast cancer
Phase 1 data to be presented 4Q 2020.
SNDX-6352
Chronic graft versus host disease
Phase 1/2 interim data potentially available throughout 2020. Data to be presented 4Q 2020.
SNDX-5613
Relapsed/refractory (R/R) acute leukemias

Latest News

  1. Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook

    WALTHAM, Mass., Jan. 10, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  2. Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease

    WALTHAM, Mass., Dec. 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  3. Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias

    WALTHAM, Mass., Dec. 9, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  4. Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update

    WALTHAM, Mass., Nov. 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  5. Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

    WALTHAM, Mass., Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  6. Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019

    WALTHAM, Mass., Oct. 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

  7. Syndax Announces Participation at Four Upcoming Investor Conferences

    WALTHAM, Mass., Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative